Reclassification of a likely pathogenic Dutch founder variant in KCNH2; implications of reduced penetrance
Jaël S. Copier(Anna Needs Neuroblastoma Answers), Elisabeth M. Lodder(Amsterdam University Medical Centers), Hennie Bikker(Amsterdam University Medical Centers), Connie R. Bezzina(Amsterdam Neuroscience), Tamara T. Koopmann(Academic Medical Center), Jasper J. van der Smagt(Utrecht University), Jamie I. Vandenberg(Victor Chang Cardiac Research Institute), Imke Christiaans(Academic Medical Center), Robin A. Bertels(Leiden University Medical Center), Saskia N. van der Crabben(ERN GUARD-Heart), Arie O. Verkerk(Amsterdam Neuroscience), Janna A. Hol(University Medical Center Utrecht), Aafke A J Lommerse(Leiden University Medical Center), Marianne Bootsma(Ave Maria University), Daniela Q.C.M. Barge‐Schaapveld(Leiden University), Arthur A.M. Wilde(Amsterdam Neuroscience), Chai‐Ann Ng(Maastricht University), Jeroen Knijnenburg(Leiden University)
Cited by 5
Related Papers
2023 ESC Guidelines for the management of cardiomyopathies
|European Heart Journal|2023|2.3k
Genotype-Phenotype Correlation in the Long-QT Syndrome
|Circulation|2001|1.8k
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome
|Circulation|2010|850